Additionally, interim findings from the ongoing phase 3 ESSENCE trial suggest that semaglutide 2.4 mg may have a disease-modifying role in metabolic dysfunction-associated steatohepatitis (MASH)
Our study demonstrates that direct cartilage protection is not only achievable but central to achieving therapeutic efficacy
Kalra, A., Yetiskul, E., Wehrle, C
Another study has highlighted FK866s potential in treating neurodegenerative diseases by modulating NAD + metabolism and reducing oxidative stress to support neuronal health 220
doi:10.4158/EP161365.GL 8
Members include surgeons (oral and maxillofacial, ENT, or plastic), pediatric dentists, orthodontists, speech pathologists, geneticists, audiologists, social workers, psychologists, and pediatricians